Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
18/09/26	CNY 65.07	+1.18%	1,809,000
17/09/26	CNY 64.31	+6.09%	1,786,946
16/09/26	CNY 60.62	+2.90%	787,312
15/09/26	CNY 58.91	+3.17%	914,210
14/09/26	CNY 57.10	+1.01%	803,800

End-of-day quote Shenzhen S.E.

More quotes

End-of-day quote Shenzhen S.E. 18/09/2026			5-day change	1st Jan Change
65.07 ^CNY	+1.18%		+15.11%	+9.05%

26/08	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
28/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	5.21B 777M 677M 640M 581M 1.09B 74.53B 1.09B 7.66B 2.96B 37.89B 2.92B 2.85B 122B	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	5.53B 826M 720M 680M 617M 1.16B 79.21B 1.16B 8.14B 3.14B 40.27B 3.1B 3.03B 130B	EV / Sales 2024	6.46x	EV / Sales 2025	32.7x
Free-Float	30.57%	Yield 2024 *	-	Yield 2025	-

26/08	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
28/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
27/02	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
24/02	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
21/01	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI
05/12	Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.	CI
24/10/25	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
13/10/25	Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million.	CI
29/09/25	Duorui Pharma Expects Control Change Amid Parents' Plan	MT

1 day	+1.18%
1 week	+15.11%
Current month	+12.58%
1 month	+19.57%
3 months	-3.04%
6 months	-16.80%
Current year	+9.05%

Tibet Duo Rui Pharmaceutical Co., Ltd. Stock

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news: Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	56.33	66
1 month	52.09	66
Current year	44.55	98.29
1 year	39.1	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	01/12/2018
Chao Li DFI	Director of Finance/CFO	47	01/05/2017
Fen Jin DFI	Director of Finance/CFO	46	01/12/2017

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	01/12/2017
Shao Zhong Zhang BRD	Director/Board Member	70	21/02/2020
Qin Deng BRD	Director/Board Member	58	21/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	+1.18%	+15.11%	+55.08%	+137.48%	777M
ELI LILLY AND COMPANY	+0.69%	+2.20%	+54.10%	+111.47%	1,028B
JOHNSON & JOHNSON	+1.15%	+2.26%	+56.33%	+68.47%	651B
ABBVIE INC.	+0.67%	+1.71%	+19.61%	+73.52%	466B
ROCHE HOLDING AG	+1.91%	+0.77%	+34.34%	+45.07%	346B
NOVARTIS AG	+1.23%	+2.44%	+18.72%	+25.88%	266B
ASTRAZENECA PLC	+0.48%	+3.75%	+9.65%	+15.84%	259B
AMGEN INC.	+1.11%	+1.74%	+35.71%	+44.07%	208B
NOVO NORDISK A/S	-6.92%	-6.08%	-31.28%	-59.00%	191B
GILEAD SCIENCES, INC.	+0.45%	+3.07%	+34.15%	+100.48%	186B
Average	+0.18%	+4.33%	+28.64%	+56.33%	360.25B
Weighted average by Cap.	+0.47%	+3.09%	+35.71%	+65.71%

	2024	2025
Net sales	241M 35.9M 31.31M 29.56M 26.85M 50.3M 3.45B 50.51M 354M 137M 1.75B 135M 132M 5.64B	154M 23.01M 20.06M 18.94M 17.2M 32.23M 2.21B 32.36M 227M 87.56M 1.12B 86.42M 84.5M 3.61B
Net income	-62.67M -9.35M -8.15M -7.7M -6.99M -13.1M -897M -13.15M -92.22M -35.59M -456M -35.13M -34.35M -1.47B	-102M -15.25M -13.29M -12.55M -11.4M -21.36M -1.46B -21.45M -150M -58.02M -744M -57.27M -56M -2.39B
Net Debt	135M 20.1M 17.52M 16.55M 15.03M 28.15M 1.93B 28.27M 198M 76.49M 980M 75.49M 73.82M 3.15B	327M 48.75M 42.51M 40.14M 36.45M 68.3M 4.68B 68.58M 481M 186M 2.38B 183M 179M 7.65B